Business
atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai's supply chain
TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in
About this update from Ataibeckley Inc.
[{"type":"text","content":"TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health. This new platform company will focus on the generation of intellectual property and further strengthen atai’s drug development pipeline of psychedelic and non-psychedelic compounds. TryptageniX will also develop scalable and environmentally friendly biosynthetic manufacturing methods for atai's naturally derived compounds. NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the launch of TryptageniX. This new platform company will specialize in both the discovery of new chemical entities (NCEs) for the atai pipeline through bioprospecting and on biosynthesis of atai's naturally derived development candidates. Both approaches are expected to further strengthen atai’s already robust intellectual property (IP) portfolio spanning psychedelic and non-psychedelic compounds. Bioprospecting refers to the search for natural products from which medicines can be developed, while biosynthesis is the production of complex molecules within living organisms or cells. Both are central to TryptageniX’s approach to the development of NCEs. In addition, the development of innovative biosynthetic methods will further optimize the scalability of compound manufacturing, allowing atai to address the escalating mental health crisis in an ecologically sustainable manner.1 “We are constantly seeking opportunities to further extend the capabilities of our platform,” said Florian Brand, Chief Executive Officer and Co-Founder of atai Life Sciences. “TryptageniX’s approach to drug discovery is highly complementary to that of EntheogeniX, our existing AI-enabled drug discovery company. The launch of TryptageniX demonstrates our ongoing commitment to harness the most promising scientific advancements of our age for the good of patients.” “atai is delighted to be collaborating with CB Therapeutics to form TryptageniX,” said Srinivas Rao, Chief Scientific Officer and Co-Founder of atai Life Sciences. “We both share a strong commitment to driving novel approaches in the treatment of mental health disorders. This is yet another important st...